The present study demonstrates that high expression of GLI-1 exhibits a poor risk feature in newly diagnosed AML patients, and it can be utilized in risk stratification remodeling and as a diagnostic predictor of the initial chemotherapeutic response especially in those who appear to have a favorable outcome. The gene discussed is GLI1; the disease is acute myeloid leukemia.